Gaetano R. Giuffrida

Catania, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications

Physical Activity, Bleeding Incidence and Health-Related Quality of Life, in Patients With Haemophilia A Without Inhibitors, Treated With Emicizumab: A Post-Hoc Descriptive Analysis of the Power Study Data.

Physical Activity, Bleeding Incidence and Health-Related Quality of Life, in Patients With Haemophilia A Without Inhibitors, Treated With Emicizumab: A Post-Hoc Descriptive Analysis of the Power Study Data.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: May 28, 2026

Haemodialysis in haemophilia B: a case report. Challenges and strategies from a nephrology perspective.

Haemodialysis in haemophilia B: a case report. Challenges and strategies from a nephrology perspective.

Journal: Journal of nephrology
Published: March 24, 2026

Refractory Primary Immune Thrombocytopenia With Bleeding and Thrombosis: A Case Report.

Refractory Primary Immune Thrombocytopenia With Bleeding and Thrombosis: A Case Report.

Journal: The American journal of case reports
Published: February 15, 2026

Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.

Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.

Journal: Annals of hematology
Published: January 30, 2026

Integrating Clinical, Functional, and Patient-Reported Outcomes in Haemophilia Care: A Delphi-Based Consensus on a New Monitoring Tool.

Integrating Clinical, Functional, and Patient-Reported Outcomes in Haemophilia Care: A Delphi-Based Consensus on a New Monitoring Tool.

Journal: Journal of clinical medicine
Published: December 18, 2025

The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study.

The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study.

Journal: Frontiers in pharmacology
Published: December 05, 2025

Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database.

Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database.

Journal: Hematology reports
Published: September 13, 2025

Clinical and prognostic implications of pituitary macroadenomas (PitNets) grading: a monocentric experience.

Clinical and prognostic implications of pituitary macroadenomas (PitNets) grading: a monocentric experience.

Journal: Pituitary
Published: February 17, 2025

Identification of Novel Mutations in Patients Affected by Gaucher Disease.

Identification of Novel Mutations in Patients Affected by Gaucher Disease.

Journal: International journal of molecular sciences
Published: February 10, 2025

Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study.

Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study.

Journal: Journal of clinical medicine
Published: August 24, 2024

Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real-Life Case Series and Literature Review.

Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real-Life Case Series and Literature Review.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: August 14, 2024

Gaucher Disease or Acid Sphingomyelinase Deficiency? The Importance of Differential Diagnosis.

Gaucher Disease or Acid Sphingomyelinase Deficiency? The Importance of Differential Diagnosis.

Journal: Journal of clinical medicine
Published: February 12, 2024
Showing 1-12 of 64

Last Updated: 09/26/2026